Clinical trials: HTLV-I Infection
HTLV-I Infection
Raltegravir for HAM/TSP
Background: Human T-cell lymphotropic virus type 1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an infection of the spinal cord.
- Trial name
- NCT01867320
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HTLV-I Infection, T Cell Leukemia
Anti-Tac for Treatment of Leukemia
The purpose of the study was to determine: (1) the toxicity and maximum tolerated dose (MTD) of humanized anti-Tac (daclizumab), (Zenapax(Registered Trademark)) in patients with adult T-cell leukemia/lymphoma (ATL); (2) to define…
- Trial name
- NCT00001941
- Testing
- daclizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
HTLV-1
Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
This study will examine the use of the humanized Mik-Beta-1 (Hu Mik-(SqrRoot) 1) monoclonal antibody in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
- Trial name
- NCT00076843
- Testing
- Hu MiK-Beta-1
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Human Immunodeficiency Virus, Hepatitis B
Notification of Donors With Positive Microbiology Markers
Each year around 200 blood donors in the UK are found to be infected with blood-borne diseases (HIV, hepatitis B, hepatitis C, and HTLV), while several others have been identified as having an increased risk of variant…
- Conditions
- Human Immunodeficiency Virus, Hepatitis B, Hepatitis C, Human T-lymphotropic Virus I & II
- Trial name
- NCT01050881
- Where
- United Kingdom
- Volunteers
- 217 people
- Sponsor
- NHS Blood and Transplant
HTLV-1-associated Myelopathy
Rituximab for HTLV-1-associated Myelopathy
Neuroprotective or anti-inflammatory strategies are invaluable in HTLV-1-associated myelopathy due to its rapid progression. We evaluated the efficacy of rituximab in patients with HTLV-1-associated myelopathy.
- Trial name
- NCT04004819
- Testing
- Rituximab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
HTLV-I Infection, Tropical Spastic Paraparesis
Evaluation of Patients With HAM/TSP
Objective: Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus.
- Trial name
- NCT00001778
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Paraparesis Spastic Tropical
Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM)
Is the valproic acid efficacy to treat TSP/HAM
- Trial name
- NCT00681980
- Testing
- Valproic acid, costicosteroids, valproid acid plus corticosteroids
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
HTLV-1 Associated Myelopathy
A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)
The objective of this study is to assess the efficacy and safety of KW-0761 after intravenous injections in subjects with HTLV-1 associated myelopathy (HAM) in Japan.
- Trial name
- NCT03191526
- Testing
- KW-0761 0.3 mg/kg IV
- Where
- 16 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Tropical Spastic Paraparesis, HTLV-1
Urological Physical Therapy in HTLV-1 With Urinary Symptoms
Urological physical therapy is described to improve urinary symptoms in patients with myelopathy or neurological dysfunction and to increase the quality of life.
- Trial name
- UROHTLV (NCT01651819)
- Testing
- Urological physical therapy
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
HTLV-1-Associated Myelopathy (HAM)
A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)
The purposes of this study is to assess the safety, tolerability, and pharmacokinetics of MT-3921 in subjects with Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy(HAM).
- Trial name
- NCT05240612
- Testing
- MT-3921
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Tanabe Pharma Corporation
Lymphoproliferation Induced by HTLV-1, HTLV-1 Adult T-cell Lymphoma / Leukemia
Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)
The purpose of this study is to evaluate the outcome (survival) of Adult T-cell leukemia / lymphoma (ATL) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome (survival) of HTLV-1…
- Conditions
- Lymphoproliferation Induced by HTLV-1, HTLV-1 Adult T-cell Lymphoma / Leukemia, HTLV-1 Infection
- Trial name
- HTLV-OBS (NCT05237245)
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Tropical Spastic Paraparesis
MRI Brain Studies in Patients With HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
This study will use three different magnetic resonance imaging (MRI) techniques to study HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/STP)-a disease of slowly progressive weakness in the legs.
- Trial name
- NCT00034723
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Human T-cell Leukemia Virus Type 1 Infection
Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load
This is a study of the effect of raltegravir on human T-cell leukemia virus type 1 (HTLV-1) viral load in asymptomatic patients. The study will enroll 14 subjects for a period of 2 months of treatment and 1 month of followup.
- Trial name
- NCT01620736
- Testing
- Raltegravir
- Sponsor
- Washington University School of Medicine
HTLV-I-Associated Myelopathy
Safety and Efficiency Study of Valproic Acid In HAM/TSP
Reversible acetylation of the histone tails plays an important role in the control of specific gene expression. Mounting evidence has established that histone deacetylase inhibitors such as Valproic Acid (VPA)selectively induce…
- Trial name
- VALPROHAM (NCT00519181)
- Testing
- Valproic Acid
- Volunteers
- 19 people
- Sponsor
- University Hospital Pierre Zobda-Quitman
HTLV-I
Natural History of HTLV-I Infection: Prospective Follow-up of a Cohort of Blood Donors in Jamaica
Human T-lymphotrophic virus type I (HTLV-I) is endemic in southern Japan and the Caribbean, but disease manifestations differ across geographic regions.
- Trial name
- NCT00339807
- Where
- Jamaica
- Volunteers
- 1,500 people
- Sponsor
- National Cancer Institute (NCI)
HTLV-I-associated Myelopathy
The HAM Infliximab Study
An open-label, non-randomised, uncontrolled, proof-of-concept study of eight patients with 'definite' HTLV-I-associated myelopathy/Tropical Spastic Paraparesis (HAM/TSP).
- Trial name
- HAM06 (NCT00823641)
- Testing
- Infliximab
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
HTLV-I-associated Myelopathy
Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial
To determine whether the use of two antiviral agents in combination will be better than placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I
- Trial name
- NCT00272480
- Testing
- Zidovudine/lamivudine
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Imperial College London
Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment.
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma, HTLV-1 Infection, NK-Cell Lymphoma, Unclassifiable
- Trial name
- NCT03075553
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate [Oncovin], cyclophosphamide, and doxorubicin…
- Conditions
- Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
- Trial name
- NCT04301076
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 19 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
HTLV-I Infections
Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1
Only 5 to 10% of patients infected with HTLV-1 develop a disease related to infection. The two most serious diseases are adult T-cell leukemia (ATL) and Tropical spastic paraparesis /HTLV-I-associated myelopathy (TSP / HAM).
- Trial name
- HAMIL28B (NCT01754311)
- Where
- 2 sites in Martinique
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- University Hospital Center of Martinique